Cargando…

Opportunities for Savings in Risk Arrangements for Oncologic Care

IMPORTANCE: As the US accelerates adoption of alternative payment through global payment models such as Accountable Care Organizations (ACOs) or Medicare Advantage (MA), high spending for cancer care is a potential target for savings. OBJECTIVE: To quantify the extent to which ACOs and other risk-be...

Descripción completa

Detalles Bibliográficos
Autores principales: Landon, Bruce E., Lam, Miranda B., Landrum, Mary Beth, McWilliams, J. Michael, Meneades, Laurie, Wright, Alexi A., Keating, Nancy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504611/
https://www.ncbi.nlm.nih.gov/pubmed/37713209
http://dx.doi.org/10.1001/jamahealthforum.2023.3124
_version_ 1785106762408394752
author Landon, Bruce E.
Lam, Miranda B.
Landrum, Mary Beth
McWilliams, J. Michael
Meneades, Laurie
Wright, Alexi A.
Keating, Nancy L.
author_facet Landon, Bruce E.
Lam, Miranda B.
Landrum, Mary Beth
McWilliams, J. Michael
Meneades, Laurie
Wright, Alexi A.
Keating, Nancy L.
author_sort Landon, Bruce E.
collection PubMed
description IMPORTANCE: As the US accelerates adoption of alternative payment through global payment models such as Accountable Care Organizations (ACOs) or Medicare Advantage (MA), high spending for cancer care is a potential target for savings. OBJECTIVE: To quantify the extent to which ACOs and other risk-bearing organizations operating in a specific geographic area (hospital referral region [HRR]) could achieve savings by steering patients to efficient medical oncology practices. DESIGN, SETTING, AND PARTICIPANTS: This observational study included serial cross-sections of Medicare beneficiaries with cancer from 2010 to 2018. Data were analyzed from August 2021 to March 2023. MAIN OUTCOMES AND MEASURES: Total spending and spending by category in the 1-year period following an index visit for a patient with newly diagnosed (incident) or poor-prognosis cancer. RESULTS: The incident cohort included 1 309 825 patients with a mean age of 74.0 years; the most common cancer types were breast (21.4%), lung (16.7%), and colorectal cancer (10.0%). The poor prognosis cohort included 1 429 973 (mean age, 72.7 years); the most common cancer types were lung (26.6%), lymphoma (11.7%), and leukemia (7.3%). Options for steering varied across markets; the top quartile market had 10 or more oncology practices, but the bottom quartile had 3 or fewer oncology practices. Total spending (including Medicare Part D) in the incident cohort increased from a mean of $57 314 in 2009 to 2010 to $66 028 in 2016 to 2017. Within markets, total spending for practices in the highest spending quartile was 19% higher than in the lowest quartile. Hospital spending was the single largest component of spending in both time periods ($20 390 and $19 718, respectively) followed by Part B (infused) chemotherapy ($8022 and $11 699). Correlations in practice-level spending between the first-year (2009) and second-year (2010) spending were high (>0.90 in all categories with most >0.98), but these attenuated over time. CONCLUSIONS AND RELEVANCE: These results suggest there may be opportunities for ACOs and other risk-bearing organizations to select or drive referrals to lower-spending oncology practices in many local markets.
format Online
Article
Text
id pubmed-10504611
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-105046112023-09-17 Opportunities for Savings in Risk Arrangements for Oncologic Care Landon, Bruce E. Lam, Miranda B. Landrum, Mary Beth McWilliams, J. Michael Meneades, Laurie Wright, Alexi A. Keating, Nancy L. JAMA Health Forum Original Investigation IMPORTANCE: As the US accelerates adoption of alternative payment through global payment models such as Accountable Care Organizations (ACOs) or Medicare Advantage (MA), high spending for cancer care is a potential target for savings. OBJECTIVE: To quantify the extent to which ACOs and other risk-bearing organizations operating in a specific geographic area (hospital referral region [HRR]) could achieve savings by steering patients to efficient medical oncology practices. DESIGN, SETTING, AND PARTICIPANTS: This observational study included serial cross-sections of Medicare beneficiaries with cancer from 2010 to 2018. Data were analyzed from August 2021 to March 2023. MAIN OUTCOMES AND MEASURES: Total spending and spending by category in the 1-year period following an index visit for a patient with newly diagnosed (incident) or poor-prognosis cancer. RESULTS: The incident cohort included 1 309 825 patients with a mean age of 74.0 years; the most common cancer types were breast (21.4%), lung (16.7%), and colorectal cancer (10.0%). The poor prognosis cohort included 1 429 973 (mean age, 72.7 years); the most common cancer types were lung (26.6%), lymphoma (11.7%), and leukemia (7.3%). Options for steering varied across markets; the top quartile market had 10 or more oncology practices, but the bottom quartile had 3 or fewer oncology practices. Total spending (including Medicare Part D) in the incident cohort increased from a mean of $57 314 in 2009 to 2010 to $66 028 in 2016 to 2017. Within markets, total spending for practices in the highest spending quartile was 19% higher than in the lowest quartile. Hospital spending was the single largest component of spending in both time periods ($20 390 and $19 718, respectively) followed by Part B (infused) chemotherapy ($8022 and $11 699). Correlations in practice-level spending between the first-year (2009) and second-year (2010) spending were high (>0.90 in all categories with most >0.98), but these attenuated over time. CONCLUSIONS AND RELEVANCE: These results suggest there may be opportunities for ACOs and other risk-bearing organizations to select or drive referrals to lower-spending oncology practices in many local markets. American Medical Association 2023-09-15 /pmc/articles/PMC10504611/ /pubmed/37713209 http://dx.doi.org/10.1001/jamahealthforum.2023.3124 Text en Copyright 2023 Landon BE et al. JAMA Health Forum. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Landon, Bruce E.
Lam, Miranda B.
Landrum, Mary Beth
McWilliams, J. Michael
Meneades, Laurie
Wright, Alexi A.
Keating, Nancy L.
Opportunities for Savings in Risk Arrangements for Oncologic Care
title Opportunities for Savings in Risk Arrangements for Oncologic Care
title_full Opportunities for Savings in Risk Arrangements for Oncologic Care
title_fullStr Opportunities for Savings in Risk Arrangements for Oncologic Care
title_full_unstemmed Opportunities for Savings in Risk Arrangements for Oncologic Care
title_short Opportunities for Savings in Risk Arrangements for Oncologic Care
title_sort opportunities for savings in risk arrangements for oncologic care
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504611/
https://www.ncbi.nlm.nih.gov/pubmed/37713209
http://dx.doi.org/10.1001/jamahealthforum.2023.3124
work_keys_str_mv AT landonbrucee opportunitiesforsavingsinriskarrangementsforoncologiccare
AT lammirandab opportunitiesforsavingsinriskarrangementsforoncologiccare
AT landrummarybeth opportunitiesforsavingsinriskarrangementsforoncologiccare
AT mcwilliamsjmichael opportunitiesforsavingsinriskarrangementsforoncologiccare
AT meneadeslaurie opportunitiesforsavingsinriskarrangementsforoncologiccare
AT wrightalexia opportunitiesforsavingsinriskarrangementsforoncologiccare
AT keatingnancyl opportunitiesforsavingsinriskarrangementsforoncologiccare